Vascular endothelial growth factor-A (VEGF) is critical for angiogenesis but fails to induce neovascularization in ischemic tissue lesions in mice lacking endothelial nitric oxide synthase (eNOS). VEGF receptor-2 (VEGFR-2) is critical for angiogenesis, although little is known about the precise role of endothelial VEGFR-1 and its downstream effectors in this process. Here we have used a chimeric receptor approach in which the extracellular domain of the epidermal growth factor receptor was substituted for that of VEGFR-1 (EGLT) or VEGFR-2 (EGDR) and transduced into primary cultures of human umbilical vein endothelial cells (HUVECs) using a retroviral system. Activation of HUVECs expressing EGLT or EGDR induced rapid phosphorylation of eNOS at Ser1177, release of NO, and formation of capillary networks, similar to VEGF. Activation of eNOS by VEGFR-1 was dependent on Tyr794 and was mediated via phosphatidylinositol 3-kinase, whereas VEGFR-2 Tyr951 was involved in eNOS activation via phospholipase C␥1. Consistent with these findings, the VEGFR-1-specific ligand placenta growth factor-1 activated phosphatidylinositol 3-kinase and VEGF-E, which is selective for VEGFR-2-activated phospholipase C␥1. Both VEGFR-1 and VEGFR-2 signal pathways converged on Akt, as dominant-negative Akt inhibited the NO release and in vitro tube formation induced following activation of EGLT and EGDR. The identification Tyr794 of VEGFR-1 as a key residue in this process provides direct evidence of endothelial VEGFR-1 in NO-driven in vitro angiogenesis. These studies provide new sites of modulation in VEGF-mediated vascular morphogenesis and highlight new therapeutic targets for management of vascular diseases. (Circ Res. 2006;99:715-722.) 
V ascular endothelial growth factor (VEGF) is essential for vascular development, angiogenesis, and revascularization after endothelial injury caused by angioplasty or stent placement. 1 Mice lacking VEGF receptor-2 (VEGFR-2) die in utero at embryonic day 8.5 (E8.5) because of a defect in vasculogenesis resulting from a failure of the migration and expansion of hematopoietic/endothelial progenitors, [2] [3] [4] whereas VEGFR-1-null mice die between E8.5 to E9.0 because of excess formation of endothelial cells that abnormally coalesce into disorganized tubules. 5 Deletion of the tyrosine kinase domain of VEGFR-1 does not impair angiogenesis, suggesting that VEGFR-1 acts as a decoy to regulate the bioavailability of VEGF for VEGFR-2 activation during development. 6, 7 However, there is now increasing evidence for the involvement of VEGFR-1 in adult angiogenesis, 8 -10 which was proposed to be largely associated with the pres-ence of VEGFR-1 in inflammatory cells, 8 or attributable to the amplification of VEGFR-2 signaling. 11 Nevertheless, direct evidence for endothelial VEGFR-1 signaling is lacking, and the current concept persists that VEGFR-2 is the critical receptor for angiogenesis.
Vasodilatation is an initiating event in sprouting angiogenesis, and nitric oxide (NO) has been identified as a key mediator in this process. 12 Independently, our laboratory and that of Sessa were the first to show that VEGF stimulates the release of NO from human umbilical vein endothelial cells (HUVECs). 13, 14 Several reports indicate that VEGFR-2 activation results in the upregulation and phosphorylation of endothelial NO synthase (eNOS) 15, 16 and increased production of cyclic GMP. 17, 18 Activation of VEGFR-1 also induces NO release and promotes reorganization of endothelial cells into capillary-like tube networks. 10 VEGF receptor activation leads to phosphorylation of specific tyrosine residues, and, via different adaptor molecules, signal transduction cascades are initiated. An array of phosphorylation sites in VEGFR-1 and VEGFR-2 have been identified, and some have been shown to associate with specific signal transduction proteins. 19 Indeed, mice carrying a phenylalanine substitution of VEGFR-2 Y1175 die in utero. 20 Previous studies showed that these signaling events involve the activation of phospholipase C␥ (PLC␥), protein kinase C (PKC), the mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt). 19 Despite these studies, it is not known whether VEGFR-1 or VEGFR-2 use a common or alternative signaling pathways in eNOS activation and angiogenesis, and the specific tyrosine residues of the VEGF receptors involved in these processes have yet to be identified.
Using a chimeric receptor system in primary endothelial cells, we demonstrate that the independent activation of either VEGFR-2 or VEGFR-1 stimulates capillary-like tube network formation on growth factor-reduced Matrigel in an NO-dependent manner. A major advantage of this chimeric approach is that it negates the possibility of chimeric receptors dimerizing with the endogenous VEGF receptors in endothelial cells, leading to a mixed-phenotype response.
Here we provide direct evidence for a new paradigm of VEGFR-1 and VEGFR-2 signaling in the initiation of NOdriven in vitro angiogenesis and identify Tyr794 of VEGFR-1 as a key residue in this process.
Materials and Methods

Materials
Recombinant VEGF and epidermal growth factor (EGF) were obtained from PeproTech-EC (London, UK). Mouse anti-eNOS monoclonal antibody was obtained from BD Transduction Laboratories (Lexington, KY), and rabbit polyclonal antibodies against phospho-eNOS at serine-1177 (p-eNOS Ser1177 ) and eNOS were purchased from Cell Signaling (Beverly, Mass). Wortmannin, LY294002, U73122, and nitro-L-arginine (L-NNA) were purchased from Calbiochem (Nottingham, UK). All other reagents were obtained from Sigma (Dorset, UK).
Cell Culture
Primary HUVECs were isolated and cultured as described previously. 10 Cells were used at passage 3 or 4 for experiments and serum starved in endothelial cell serum-free medium (Gibco-BRL, UK) supplemented with 0.2% BSA for 24 hours before stimulation.
Transduction of Chimeric Receptors in HUVECs
The chimeric VEGF receptors used in this study comprise the intracellular and transmembrane domains of VEGFR-1 (EGLT) or VEGFR-2 (EGDR) fused to the extracellular domain of the human EGF receptor. As EGF does not bind to VEGF receptors, it will not activate the endogenous VEGF receptors. The chimeric receptors EGLT and EGDR and their tyrosine-to-phenylalanine and deletion mutants (EGLT-Y794F, EGLT-793S, EGDR-Y951F, EGDR-Y1054F, and EGDR-Y1059F) were generated and cloned into the pMMP retroviral vector, and retrovirus-containing cell supernatant was harvested and used immediately to infect HUVECs. 21 Following 16 hours of incubation, the medium was replaced with fresh growth medium and the HUVECs used 48 hours after infection. The expression of chimeric receptors in HUVECs following retroviral transduction was demonstrated by immunoprecipitation and Western blotting (see Figure 1A ).
Adenovirus Infection of HUVECs
Recombinant adenovirus encoding dominant-negative Akt (Akt-dn) and PTEN (Phosphatase and TENsin homolog deleted on chromosome 10) under the control of the CMV early promoter and an empty control virus were propagated in HEK293 cells, purified on CsCl gradients, titered, and stored at Ϫ80°C in 4% sucrose buffer. HUVECs were plated on 6-well dishes and infected with adenovirus in low-serum growth medium at a multiplicity of infection (moi) of 100 overnight.
Western Blotting
Cells lysates were immunoblotted as described previously. 21 Membranes were probed with an anti-eNOS monoclonal antibody (1:1000) or rabbit polyclonal antibodies against phospho-eNOS-Ser 1177 (1:1000) at 4°C overnight. Proteins were visualized using the ECL detection kit (Amersham-Pharmacia, UK).
NO Release
Total NO in conditioned media was assayed as nitrite, the stable breakdown product of NO, using a Sievers NO chemiluminescence analyzer (Analytix, Sunderland, UK) as described previously. 10
Tube Formation Assay
The formation of capillary-like structures was examined on growth factor-reduced Matrigel in 24-well plates as described previously. 10 Tube formation was quantified by measuring the total tube length in five random ϫ200 power fields per well using a Nikon phasecontrast inverted microscope with Image ProPlus image analysis software (Media Cybernetics, Silver Spring, Md). Mean total tube length was calculated from 3 independent experiments performed in duplicate.
Statistics
All data are expressed as the mean (ϮSEM). Statistical comparisons were performed using 1-way ANOVA followed by the Student-Newman-Keuls test as appropriate. Statistical significance was set at a value of PϽ0.05.
Results
Tyrosine 794 of VEGFR-1 Is Essential for Activation of eNOS
The stimulation of HUVECs with VEGF induced a rapid transient increase in phosphorylation of eNOS at Ser1177, which reached a maximum at 2 minutes ( Figure 1B ). HUVECs expressing EGLT (HUVEC EGLT ) or EGDR (HUVEC EGDR ) produced similar patterns of eNOS phosphorylation in response to EGF, indicating that both VEGFR-1 and VEGFR-2 receptors are capable of activating eNOS. No response was observed in control HUVECs expressing LacZ or uninfected HUVECs following EGF stimulation (data not shown). Stimulation of HUVEC EGLT or HUVEC EGDR cells with EGF produced a similar time-dependent increase in NO release compared with VEGF-induced release in wild-type HUVECs ( Figure 1C ). These results were confirmed using the VEGF receptor-specific ligands placenta growth factor-1 (PlGF-1) and VEGF-E ( Figure IIB in the online data supplement, available at http://circres.ahajournals.org).
To identify the tyrosine residues of VEGFR-1 involved in the activation of eNOS, we used VEGFR-1 mutant (EGLT-Y794F), where Tyr794 was replaced with phenylalanine, and a truncated mutant (EGLT-793S), where a stop codon was introduced at amino acid 794. EGF had little effect on eNOS phosphorylation ( Figure 1D ) or NO production ( Figure 1E ) in HUVEC EGLT-Y795F or HUVEC EGLT-793S , indicating that Tyr794 of VEGFR-1 is essential for VEGF-mediated eNOS activation and NO release.
In the VEGFR-2 mutants, HUVEC EGDR-Y951F showed decreased phosphorylation of eNOS at Ser1177 ( Figure 1F ) and a greater than 50% reduction in NO release at 10 and 30 minutes of stimulation with EGF ( Figure 1G ). Mutations in the VEGFR-2 catalytic domain at Tyr1054 decreased NO release without apparent reduction in eNOS phosphorylation at Ser1177, whereas loss of Tyr1059 inhibited both NO release and eNOS phosphorylation in HUVEC EGDR-Y1059F ( Figure 1F and 1G ).
Tyrosine 794 of VEGFR-1 Is Essential for In Vitro Angiogenesis
To investigate the relative activity of VEGFR-1 and VEGFR-2 on endothelial cell capillary-like tube formation, HUVECs were plated onto growth factor-reduced Matrigel and mean total tube length was quantified. EGF treatment of either HUVEC EGLT or HUVEC EGDR led to an increase in the formation of tubular networks (Figure 2A and 2B). To determine whether NO is an essential mediator of both VEGFR-1-and VEGFR-2-induced angiogenesis, HUVEC EGLT or HUVEC EGDR were preincubated with the NOS inhibitor L-NNA before stimulation with EGF. The addition of the 500 mol/L L-NNA completely abolished EGF-stimulated tube formation in both HUVEC EGLT and HUVEC EGDR (Figure  2A and 2B).
To demonstrate that VEGFR-1 Tyr794 is also required for capillary tube formation, HUVEC EGLT-Y794F or HUVEC EGLT-793S were stimulated with EGF for 24 hours and the formation of tubular networks was assessed. Neither HUVEC EGLT-Y794F nor HUVEC EGLT-793S responded to EGF stimulation, indicating that Tyr794 of VEGFR-1 is essential for in vitro angiogenesis ( Figure 2C ; see also supplemental Figure IA ). In addition, when and VEGFR-2 in HUVECs and EGLT and EGDR in transduced HUVECs, immunoprecipitated with antibodies against the EGF receptor extracellular domain and immunoblotted with antibodies raised against the VEGFR-1 and VEGFR-2 intracellular domain. HUVECs were stimulated with VEGF (10 ng/mL), and HUVECs expressing the EGLT or EGDR chimeric receptors were stimulated with EGF (10 ng/mL). B, Phosphorylation of eNOS Ser1177 (p-eNOS Ser1177 ) and eNOS were detected by Western blotting. C, NO measured in cell supernatants. HUVECs expressing the EGLT and its mutants 793S and Y794F were stimulated with EGF. D, Immunoblotted p-eNOS Ser1177 and eNOS. E, Release of NO from these cells. F, HUVECs transduced with EGDR and its mutants Y951F, Y1054F, and Y1059F were incubated with EGF were Western blotted for p-eNOS Ser1177 and eNOS. G, NO release from these cells. NO was measured in cell supernatants using a Sievers chemiluminescent NO analyzer and background subtracted. Results are the mean (ϮSEM) of growth factor-stimulated cells minus the basal NO level of 5 independent experiments. *PϽ0.05, **PϽ0.01, ***PϽ0.001 vs control; †PϽ0.001 vs EGLT; §PϽ0.05, § §PϽ0.001 vs EGDR.
NO donor (glyco-S-nitroso-N-penicillamine [glyco-SNAP], 10 mol/L) or a membrane-permeable stable cGMP analog (8-bromo-cGMP, 100 mol/L) was added to HUVEC or HUVEC EGLT-793S , they formed capillary-like tubes ( Figure 2D ; supplemental Figure IB) .
Interestingly, HUVEC EGDR-Y951F and HUVEC EGDR-Y1054F induced the formation of tubular networks on stimulation with EGF despite the fact that these mutations resulted in greater than 50% reduction in NO release ( Figure 2E ; supplemental Figure IC ). This suggests that there may be a critical threshold level of NO, below which tube formation fails to occur. As expected, HUVEC EGDR-Y1059F , which did not induce NO release, failed to undergo angiogenesis ( Figure 2E ). HUVEC EGDR-Y1059F formed capillary networks when exposed to the NO donor glyco-SNAP or 8-bromo-cGMP ( Figure 2F ; supplemental Figure ID ).
VEGFR-1-Mediated eNOS Activation Is Dependent on PI3K Activity
To investigate the role of PI3K signaling in eNOS activation via VEGFR-1 or VEGFR-2, both pharmacological inhibitors and the dominant-negative p85 subunit (p85-dn) of PI3K were used. HUVEC EGLT and HUVEC EGDR were pretreated with 100 nmol/L Wortmannin or 15 mol/L LY294002 for 10 minutes and stimulated with EGF for 2 minutes to determine the level of eNOS phosphorylation. Both Wortmannin and LY294002 strongly inhibited EGF-induced eNOS phosphorylation in HUVEC EGLT but not in HUVEC EGDR ( Figure 3A) . To confirm conclusively that PI3K is essential for VEGFR-1-mediated eNOS phosphorylation, p85-dn was coexpressed with EGLT and EGDR and the cells stimulated with EGF. No increase in eNOS phosphorylation was detected in the p85-dn-expressing HUVEC EGLT , confirming that eNOS activation is via PI3K ( Figure 3B ). In contrast, the expression of p85-dn in HUVEC EGDR did not inhibit EGFinduced eNOS phosphorylation ( Figure 3B) . Consistent with the observed lack of eNOS phosphorylation in LY294002treated HUVEC EGLT , inhibition of PI3K significantly decreased the release of NO in HUVEC EGLT but had no effect on HUVEC EGDR (Figure 3C ), demonstrating the requirement for PI3K in VEGFR-1-mediated eNOS activation. These findings were confirmed using HUVEC EGLT and HUVEC EGDR infected with adenoviruses expressing wild-type PTEN (PTEN-wt) or empty control virus. EGF-stimulated NO release from HUVEC EGLT , but not HUVEC EGDR , was blocked by the overexpression of PTEN-wt ( Figure 3D ).
VEGFR-2 Activates eNOS via PLC␥1
The activation of VEGFR-2, but not VEGFR-1, with receptor selective VEGF ligands increased the phosphorylation PLC␥1 (supplemental Figure IIA) . As VEGFR-2 activity was independent of PI3K, HUVEC EGLT or HUVEC EGDR were preincubated with the PLC inhibitor U73122 before stimulation with EGF. PLC inhibition prevented EGF-induced eNOS Figure 2 . Tyrosine residue 794 of VEGFR-1 is required for VEGF-mediated tube formation. HUVECs expressing EGLT or EGDR and their mutants were seeded on growth factor-reduced Matrigel for 24 hours, and mean total tube length was used to assess in vitro tube formation. Phase contrast images (A) and histogram of mean total tube per ϫ200 field (B) demonstrating that EGF (10 ng/mL) stimulates EGLT and EGDR tube formation, which is blocked by L-NNA (500 mol/L). HUVECs expressing the EGLT mutants 793S and Y794F do not show increased mean total tube length following EGF stimulation (C) but are still capable of forming tubes in the presence of the NO donor glyco-SNAP-1 (10 mol/L) or 8-Bromo-cGMP (100 mol/L) (D). In vitro angiogenesis of HUVECs expressing EGDR, as well as the Y951F, Y1054F, and Y1059F mutants following incubation with EGF (10 ng/mL) (E) and in the presence or absence of 10 mol/L glyco-SNAP-1 or 100 mol/L 8-Bromo-cGMP (F). Total tube length was measured in 5 random ϫ200 fields per well using Image ProPlus analysis software and expressed in micrometers per field. Results are the mean (ϮSEM) of 3 to 5 independent experiments performed in duplicate. *PϽ0.05, **PϽ0.01 vs control; †PϽ0.01 vs EGF.
phosphorylation in HUVEC EGDR but had no effect on eNOS activation in HUVEC EGLT (Figure 4A ). In addition, pretreatment with U73122 significantly attenuated EGF-mediated release of NO in HUVEC EGDR ( Figure 4B ). However, U73122 had no effect on EGF-induced NO release in HUVEC EGLT , demonstrating that VEGFR-2-mediated eNOS activation is regulated by PLC␥ ( Figure 4B ). These findings were confirmed by RNA interference-mediated knockdown of PLC␥1, which inhibited the release of NO stimulated via VEGFR-2 but not by VEGFR-1 (supplemental Figure IIB) .
Akt Activation Is Essential for VEGF-Mediated NO Release and Angiogenesis
As the phosphorylation of eNOS at Ser1177 is associated with Akt activation, 22 we investigated whether Akt is a common mediator of both VEGFR-1-and VEGFR-2-driven eNOS activation and tube formation. Both the VEGFR-1and VEGFR-2-selective ligands PlGF-1 and VEGF-E induced a rapid increase in Akt phosphorylation at Ser473, consistent with its activation (see supplemental Figure IIIA ). To examine the requirement of Akt for VEGFR-1-or VEGR-2mediated eNOS activity and tube formation, HUVEC EGLT or HUVEC EGDR were infected with adenoviruses expressing either Akt-dn or constitutively active myristylated Akt (myr-Akt) or empty vector control at an moi of 100 for 18 hours before stimulation with EGF. The overexpression of Akt-dn blocked NO release from EGF-stimulated HUVEC EGLT and HUVEC EGDR to control levels ( Figure 5A ) and also inhibited in vitro angiogenesis ( Figure 5B ; supplemental Figure IIIC) . In contrast myr-Akt strongly promoted NO release and tube formation, independent of EGF stimulation and chimeric receptor stimulation (data not shown). These findings were confirmed using a pharmacological Akt inhibitor (Akt-i) (supplemental Figure  IIIB) . Collectively, these results demonstrate that both eNOS and Akt are required for VEGFR-1-and VEGFR-2-mediated angiogenesis. 
Discussion
In this study, we show conclusively that VEGFR-1 is a signaling receptor for eNOS activation and in vitro angiogenesis. We demonstrate, to our knowledge, for the first time that chimeric VEGF receptor mutants lacking the ability to produce NO fail to induce capillary network formation, providing direct evidence for NO as a second messenger for VEGF-driven angiogenesis. Furthermore, both the activation of eNOS and endothelial tube network formation are dependent on Tyr794 of VEGFR-1 and mediated via the PI3K pathway, whereas VEGFR-2 uses PLC␥ to stimulate these activities and Tyr951 is partially required. However, VEGF receptor pathways converge on Akt, which appears to be the common mediator of VEGF-stimulated eNOS activation and in vitro angiogenesis ( Figure 6 ). This is consistent with a recent report showing that the loss of Akt1, but not Akt2, markedly reduces VEGF-stimulated NO accumulation in murine lung endothelial cells. 23 Relatively little is known about the signaling proteins that associate with VEGFR-1. Earlier studies reported that VEGFR-1 could activate PLC␥ in NIH3T3 fibroblasts 24, 25 and monocytes. 26 One study reported PLC␥ activation, 27 although another failed to detect this in porcine aortic endothelial cells overexpressing VEGFR-1. 28 Here we dem-onstrate not only the importance of Tyr794 of VEGFR-1 for NO-mediated angiogenesis but also show that this process is mediated in a PI3K-dependent and PLC␥-independent manner. In a yeast 2-hybrid system, Tyr794 and Tyr1169 interact with PLC N-SH2 binding domains. 29, 30 Ito and colleagues identified 2 major (Tyr1213, Tyr1242) and minor (Tyr1327, Tyr1333) VEGFR-1 phosphorylation sites, and, of these, Tyr1213 and 1333 were found to associate with of PLC␥, Grb2, Shp2, Crk, and Nck in vitro and increase the phosphorylation of PLC␥, Shp2, and Crk in porcine aortic endothelial cells. 27, 31 Although no association of p85 with VEGFR-1 was detected, the juxtamembrane region of VEGFR-1 containing Tyr794 and Tyr815 was not examined in these studies. 27, 31 VEGF failed to induce the activation of PI3K in porcine aortic endothelial cells overexpressing VEGFR-1. 28, 31 In contrast to these studies, p85 SH2 domain was shown to bind Tyr1213 of VEGFR-1 in vitro, 29 which is reported to be a key site activated by VEGF. 11 Our study demonstrates the role of PI3K in VEGFR-1-mediated eNOS activation as transduction of dominant-negative p85 subunit of PI3K into EGLTexpressing endothelial cells inhibits eNOS phosphorylation. Indeed, using chimeric receptor approaches, we showed that VEGFR-1 activates PI3K to negatively regulate VEGFR-2induced proliferation. 32, 33 This activation of PI3K is dependent on VEGF Tyr794, 21 which is also responsible for NO-mediated angiogenesis in vitro. One explanation for the discrepancy in VEGFR-1 signaling detected in fibroblasts, monocytes, and transformed porcine aortic endothelial cells compared with the primary endothelial cell cultures used in this study is that the former may lack the appropriate repertoire of adaptor proteins necessary to recapitulate the exact signal transduction events. 25 In this study, we demonstrate that VEGFR-2-mediated NO release is dependent on PLC␥ activity as U73122 blocked EGF-induced NO release in HUVEC EGDR but not in HUVEC EGLT . In addition, we showed that Tyr771 of PLC␥1 is phosphorylated by the VEGFR-2-specific ligand VEGF-E (and not VEGFR-1), leading to NO release that is inhibited by PLC␥1 knockdown (supplemental Figure II) . The phosphor- ylation of PLC␥ was reported to be associated with the activation of VEGFR-2 expressed in NIH3T3 fibroblasts, 25 and VEGF increases phosphorylation of PLC␥1 Tyr771 and eNOS Ser1177 in HUVECs. 16 Several autophosphorylation sites have been identified in the cytoplasmic domain of VEGFR-2, 34, 35 and the binding of PLC␥ Src homology (SH2) domains is associated with various tyrosine residues on this receptor. 29 Tyr951 is important for VEGFR-2-mediated RhoA activation and the migration but not proliferation of endothelial cells. 36 However, its role in NO release and angiogenesis had not been investigated. Here we show that a loss of this residue results in a greater than 50% reduction in NO release. Tyr951, which lies in the kinase insert domain, is a docking site for PLC␥ 37 and the VEGF receptor-associated phosphatase/T-cell-specific adapter molecule. 38 Recently, the phosphorylation of Tyr951 was shown regulate F-actin filament reorganization and cell migration via VEGF receptorassociated phosphatase/T-cell-specific adapter molecule. 39 Interestingly, Tyr951 is phosphorylated in a subpopulation of endothelial cells predominantly in vessels lacking pericytes, suggesting that it may be associated with sites of active angiogenesis. 39 As the loss of Tyr951 resulted in a partial reduction of NO release, it is likely that other tyrosine residues in VEGFR-2 are responsible for the generation of NO. VEGFR-2 Tyr1175, which also binds and activates PLC␥ to promote endothelial cell migration, 35 is likely to be involved. Indeed, mice carrying a phenylalanine substitution of this residue die in utero because of a failure of endothelial cell proliferation and differentiation. 20 Tyr1054 and Tyr1059 lie within the catalytic domain of VEGFR-2 and are important for maximal receptor activation, as their combined mutation leads to a 90% reduction in receptor phosphorylation. 34 As expected, these residues are essential for full receptor activity and loss of Tyr1059 appeared to be the most critical in VEGFR-2-driven NO-mediated in vitro angiogenesis.
During murine yolk sac vasculogenesis, endoderm-derived NO is important for the formation of the primary capillary plexus, 40 and eNOS has been linked to vasculogenesis in the adult. Endothelial NOS-null mice exhibit impaired mobilization of bone marrow progenitor cells in ischemia, which cannot be restored by bone marrow transplantation. 41 VEGF promotes the survival of endothelial progenitor cells and hematopoietic stem cells via VEGFR-2 in the bone marrow 42, 43 and exogenous VEGF or PlGF markedly potentiate megakaryocyte maturation, suggesting a role for VEGFR-1 in these processes. 44 VEGFR-1 is involved in the mobilization of bone marrow-derived circulating progenitors during neoangiogenesis 45, 46 and the homing of bone marrow-derived hematopoietic progenitor cells to tumor-specific premetastatic sites. 47 Our identification of VEGFR-1 Tyr794 as key residue for the activation of eNOS and neovascularization suggests that it may also hold true for VEGFR-1-mediated signaling in mobilization of bone marrow progenitor cells. Collectively, these observations, together with our findings, indicate that blockade of VEGFR-2 alone might be insufficient to achieve maximal therapeutic benefit in angiogenesisdriven pathologies.
